GoAI
Get started
Teladoc Health, Inc. logo

Teladoc Health, Inc.

TDOC

NYSEHealthcareMedical - Healthcare Information Services

Open in GoAI

Regular session

$6.345

−$0.045 · -0.70%

Aug 24, 10:11 AM ET

TDOC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

79

Undervalued

Momentum

59

Neutral

Sentiment

53

Mixed

Risk resilience

47

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Charles Divita
Listed since
Jun 30, 2015
Employees
5,124

Market position

Day range

Current $6.345

52-week range

Current $6.345

Open
$6.375
Previous close
$6.39
Volume
327.59K
0.07× average
Average volume
4.96M
Average daily volume
Market cap
1.15B USD
Beta
2.13
Market reference 1
50-day average
$8.032
-21.00% below average
200-day average
$6.7431
-5.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.49B USD
P/E (TTM)
-6.41×
P/B (TTM)
0.87×
P/S (TTM)
0.46×
EV / EBITDA
10.13×
Earnings yield
-16.24%
Free cash flow yield
23.14%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
73.53%
Operating margin
-6.98%
Net margin
-7.13%
Return on equity
-14.46%
Return on assets
-6.46%
Return on invested capital
-8.26%

Financial health

Debt / equity
0.79×
Current ratio
2.69×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends135%-121%-376%-631%Gross margin, FY2021: 68.01%Gross margin, FY2022: 69.09%Gross margin, FY2023: 70.80%Gross margin, FY2024: 70.76%Gross margin, FY2025: 69.50%Operating margin, FY2021: -13.07%Operating margin, FY2022: -567.27%Operating margin, FY2023: -9.55%Operating margin, FY2024: -39.73%Operating margin, FY2025: -10.39%Net margin, FY2021: -21.09%Net margin, FY2022: -567.53%Net margin, FY2023: -8.47%Net margin, FY2024: -38.97%Net margin, FY2025: -7.92%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 68.01%. Gross margin FY2022 69.09%. Gross margin FY2023 70.80%. Gross margin FY2024 70.76%. Gross margin FY2025 69.50%. Operating margin FY2021 -13.07%. Operating margin FY2022 -567.27%. Operating margin FY2023 -9.55%. Operating margin FY2024 -39.73%. Operating margin FY2025 -10.39%. Net margin FY2021 -21.09%. Net margin FY2022 -567.53%. Net margin FY2023 -8.47%. Net margin FY2024 -38.97%. Net margin FY2025 -7.92%.

Income trends

Revenue

2.53B USD-1.54%

Operating income

−262.96M USD+74.24%

Net income

−200.32M USD+79.99%
Income trends across reported periods4.23B USD−2.28B USD−8.78B USD−15.29B USDRevenue, FY2021: 2.03B USDRevenue, FY2022: 2.41B USDRevenue, FY2023: 2.6B USDRevenue, FY2024: 2.57B USDRevenue, FY2025: 2.53B USDOperating income, FY2021: −265.63M USDOperating income, FY2022: −13.65B USDOperating income, FY2023: −248.55M USDOperating income, FY2024: −1.02B USDOperating income, FY2025: −262.96M USDNet income, FY2021: −428.79M USDNet income, FY2022: −13.66B USDNet income, FY2023: −220.37M USDNet income, FY2024: −1B USDNet income, FY2025: −200.32M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.03B USD. Revenue FY2022 2.41B USD. Revenue FY2023 2.6B USD. Revenue FY2024 2.57B USD. Revenue FY2025 2.53B USD. Operating income FY2021 −265.63M USD. Operating income FY2022 −13.65B USD. Operating income FY2023 −248.55M USD. Operating income FY2024 −1.02B USD. Operating income FY2025 −262.96M USD. Net income FY2021 −428.79M USD. Net income FY2022 −13.66B USD. Net income FY2023 −220.37M USD. Net income FY2024 −1B USD. Net income FY2025 −200.32M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.53B USD2.57B USD2.6B USD2.41B USD2.03B USD
Cost of goods sold771.59M USD751.27M USD760.03M USD743.99M USD650.26M USD
Gross profit1.76B USD1.82B USD1.84B USD1.66B USD1.38B USD
Research and development277.92M USD307.27M USD348.52M USD333.63M USD311.88M USD
Selling, general, and administrative1.09B USD1.35B USD1.37B USD1.3B USD1.11B USD
Operating expenses2.02B USD2.84B USD2.09B USD15.32B USD1.65B USD
Interest income36.77M USD57.07M USD46.78M USD12.67M USD776K USD
Interest expense19.71M USD23.8M USD22.28M USD21.94M USD81.14M USD
Depreciation and amortization363.12M USD240.51M USD254.11M USD209.93M USD207.57M USD
Operating income−262.96M USD−1.02B USD−248.55M USD−13.65B USD−265.63M USD
Net income−200.32M USD−1B USD−220.37M USD−13.66B USD−428.79M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-1.14
FY2025
Latest fiscal-year revenue
2.53B USD
FY2025 · -1.54% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend7.21-26.18-59.56-92.95FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend2.66B2.43B2.2B1.98BFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

42 ratings
Strong buy00%
Buy1536%
Hold2764%
Sell00%
Strong sell00%

TDOC news

prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle…

Read source
globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Teladoc Health, Inc. – TDOC

NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). Such investors are advised to contact Danielle…

Read source
prnewswire.com

Did Teladoc Health, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be…

Read source
defenseworld.net

California State Teachers Retirement System Acquires 104,160 Shares of Teladoc Health, Inc. $TDOC

California State Teachers Retirement System raised its stake in shares of Teladoc Health, Inc. (NYSE: TDOC) by 61.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and…

Read source
prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle…

Read source
globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). Such investors are advised to contact Danielle…

Read source

TDOC peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,244.42

-0.87%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.65

+0.15%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$264.58

-0.14%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$150.76

-1.16%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$398.38

+2.12%

Novartis AG logo

NVS

Novartis AG

$157.51

-0.85%

ETFs holding TDOC

Funds reporting this stock among their holdings, ordered by reported position size.

Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
43.97M
Weight
0.14%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.52+0.05%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
38.52M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.83-0.37%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
29.8M
Weight
0.04%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.48-0.49%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
27.88M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$303.43-0.44%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
17.68M
Weight
0.03%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.34+0.06%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
13.93M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.76-0.72%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
10.84M
Weight
0.07%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.96+0.06%
Schwab Fundamental U.S. Small Company Index ETF logoSchwab Fundamental U.S. Small Company Index ETFFNDA
Market value
7M
Weight
0.08%
AUM
9.26B USD
Expense ratio
0.25%
Price / 1D
$37.64-0.24%

Continue in GoAI

Research TDOC

research.disclaimer